Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels

Details for Australian Patent Application No. 2005202122 (hide)

Owner Celgene Corporation

Inventors Muller, George; Man, Hon-wah

Agent Pizzeys

Pub. Number AU-B-2005202122

Parent 22785

Filing date 18 May 2005

Wipo publication date 30 June 2005

Acceptance publication date 31 January 2008

International Classifications

C07D 413/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/4245 (2006.01) - Oxadiazoles

A61K 31/428 (2006.01) - condensed with carbocyclic rings

C07D 417/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

2 June 2005 Complete Application Filed

30 June 2005 Application Open to Public Inspection

  Published as AU-B-2005202122

31 January 2008 Application Accepted

  Published as AU-B-2005202122

6 March 2008 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 12 Feb 2008. Address for service in Australia - PIZZEYS GPO Box 1374 Brisbane QLD 4001

29 May 2008 Standard Patent Sealed

31 July 2008 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 12 Feb 2008

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005202123-Treatment of Lupus Nephritis with AntiCD40L Compounds

2005202121-Improvements Relating To Paperboard